OncoLens, a pioneer in tumor board and cancer treatment planning software solutions, announced it has raised a Pre-Series A funding of $2.5 million led by our firm. Other investors in the round include Atlanta Technology Angels, and the Robbins Fund. All three were prior investors in the company’s seed round and are reaffirming their commitment to the business with this second funding round.
According to the American Cancer Society, nearly 1.76 million new cancer cases were diagnosed in the United States in 2019, with 606,880 cancer deaths reported. OncoLens delivers software solutions that help cancer centers more efficiently conduct multi-specialty cancer case reviews and achieve Commission on Cancer (CoC), National Accreditation Program for Breast Centers (NAPBC), or National Accreditation Program for Rectal Cancer (NAPRC) accreditations.
On the investment, Mark Buffington, CEO and co-founder of BIP Capital, shared:
“With the growing number of complex cancer cases and pressure for hospitals to improve patient outcomes, OncoLens allows cancer centers to reduce the time and resources it takes for multi-disciplinary case collaboration, early identification of precision medicine-based solutions, and relevant clinical trials for patients. We’ve seen tremendous uptick in the OncoLens business over the past year, including rapid market adoption and significant product line growth. We’re proud to partner with OncoLens and view it as one of the top emerging healthcare companies in the Southeast.”
This investment round will help OncoLens to continue to expand the capabilities of its solutions and grow sales and marketing resources.
>> Read more on PR Web.